SOURCE: VaxDesign Corporation

October 22, 2007 10:00 ET

VaxDesign Receives Prestigious R&D 100 Award

MIMIC™ Technology Models the Human Immune System

ORLANDO, FL--(Marketwire - October 22, 2007) - VaxDesign Corporation announced today that R&D Magazine has named the VaxDesign MIMIC™ technology as a recipient of the 2007 R&D 100 Awards. The MIMIC™ technology creates a model of the human immune system that fits into a space the size of a small coin. These miniature immune systems can predict the human immune response to vaccines and other products, acting as a "clinical trial in a test tube" before new products are tested in humans.

The MIMIC™ (Model IMmune In vitro Construct) technology uses human white blood cells to create a fully functional immune system that mimics the immune system of the cell donor. MIMIC™ models can rapidly simulate a clinical trial, including the effect of a vaccine or drug on human population subgroups, where responses can be clustered based on genetic diversity, age, gender, and other factors. The models reproduce both innate and adaptive immune responses, and exhibit both humoral and cellular immunity. The models use an automated platform that enables the evaluation of thousands of products per week. VaxDesign anticipates that the MIMIC™ technology will increase success in clinical trials, reducing the time and cost for development of vaccines and other products that interact with the immune system.

"We're extremely pleased to be recognized by this award," said William Warren, Ph.D., President and CEO of VaxDesign, "The MIMIC™ technology is an exciting development in the field of immunology. We believe that our technology has the potential to reduce or replace the use of laboratory animals in these applications while providing more accurate and reliable information than is currently attainable before human clinical trials begin. Pharmaceutical companies can use this information to guide the design of more rapid and incisive clinical trials. Most of all, this award validates the dedication and skill of our scientists."

About the R&D 100 Awards

Started in 1963, the R&D 100 Awards has been called the "The Oscars of Invention" by the Chicago Tribune. All entries are initially judged by outside experts chosen from among professional consultants, university faculty, and industrial researchers with superior expertise and experience in the areas they are judging. The winning of an R&D 100 Award provides a mark of excellence known to industry, government, and academia as proof that the product is one of the most innovative ideas of the year.

About VaxDesign

VaxDesign develops, manufactures, and markets its proprietary MIMIC™ (Modular IMmmune In vitro Construct) models of the human immune system. The MIMIC™ technology functionally recapitulates the human immune system in an elegantly simple, fully automated format. Our technology predicts the immune reactivity and efficacy of vaccines and certain classes of drugs before they are tested in humans. This "clinical trial in a test tube" may reduce the risk and expense of human clinical trials and may someday replace animal testing for these applications. Development of the MIMIC™ technology was funded by DARPA under the Rapid Vaccine Assessment program.

Contact Information

  • Press Contacts:
    Michael D. Rivard
    Vice President of Corporate Development
    VaxDesign Corporation
    Email Contact